HIV in Hong Kong: patterns, transmission, and burden over time

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational cohort study collects data on adults newly diagnosed with HIV in Hong Kong over four years. It combines self-reported behavioral and network information with clinical data such as CD4, viral load, and RNA sequencing to describe HIV-1 subtypes and transmission clusters. The goal is to map epidemiologic trends, understand how transmission routes relate to subtypes, and quantify changes in the population burden. Blood samples and medical records are used to support molecular and epidemiologic analyses. Results will describe prevalent patterns and the dynamics of HIV in the community.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* adult of age 18 or above, who are
* people living with HIV, and
* attending the service of an HIV specialist clinic in the public service in Hong Kong

Exclusion Criteria:

* travelers or visitors who are temporarily staying in Hong Kong
* prisoners
* patients with mental illnesses who are unable to make informed decision
* patients whose HIV diagnosis was made outside Hong Kong and whose treatment have already started.

Where it's running

• S.H. Ho Research Centre for Infectious Diseases
  North Point, Hong Kong Recruiting

Study contacts

• Principal investigator: Shui Shan S Lee, MD — Chinese University of Hong Kong
• Study coordinator: Shui Shan Lee, MD
• Email: sslee@cuhk.edu.hk
• Phone: +85261703177

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Restarting HIV treatment with a single-pill regimen (B/F/TAF) after a treatment gap

  This study tests whether quickly restarting ART with the single-pill regimen B/F/TAF is safe and effective for people with HIV who have had a treatment interruption of at least 12 weeks.

  Recruiting at 10 sites Phase 4 CAN Community Health · Clearwater, Florida and 9 other locations · NCT07476339

• Weekly long-acting HIV-1 meds switch for people with undetectable virus

  This study tests whether switching to weekly oral long-acting HIV medicines works as well as staying on current daily pills for people with HIV who already have an undetectable viral load.

  Recruiting at 2 sites Phase 2 Gilead Sciences · Ft. Pierce, Florida and 1 other locations · NCT07841990

• GS-0415 safety and PK in people with HIV on ART

  This study tests GS-0415 in adults with HIV who are on stable ART to see if it is safe, tolerable, and how the drug behaves in the body.

  Recruiting at 15 sites Phase 1 Gilead Sciences · Los Angeles, California and 15 other locations · NCT07719491

• Gilead study of GS-3242 with Lenacapavir for people starting HIV treatment compared with Biktarvy

  This study tests whether injecting GS-3242 with Lenacapavir can work as well as Biktarvy for people newly starting HIV treatment.

  Recruiting at 19 sites Phase 2/3 Gilead Sciences · Torrance, California and 20 other locations · NCT07708727

• RNA-based vaccine BNT168 safety and immune response in adults with or without HIV

  A first-in-human study tests whether the RNA vaccine BNT168 is safe and can trigger immune responses in adults both with and without HIV.

  Recruiting at 3 sites Phase 1 BioNTech SE · Houston, Texas and 3 other locations · NCT07698600

• Long-acting LEN/TAB/ZAB regimen vs daily HIV meds in adults with suppressed HIV-1

  This study tests whether switching to an injectable, long-acting combination (lenacapavir, teropavimab, zinlirvimab) can keep HIV-1 under control in adults who are already virally suppressed on stable oral therapy.

  Recruiting at 2 sites Phase 3 Gilead Sciences · Berkeley, Michigan and 1 other locations · NCT07683000

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.